Medispa Valuation Multiples UK 2026
UK medispa clinics are selling at 4x to 12x EBITDA in 2026. Learn what drives aesthetics valuations, who is buying, and how to prepare your clinic for a premium exit.
DealFlowAgent is the UK and US's only M&A advisory and brokerage firm specialising in medispa and aesthetic clinic businesses. We help owners secure multiple acquisition offers at higher valuations.
Sell your medispas & aesthetic clinics businessMedispa Valuation Multiples UK 2026
The UK aesthetics market is on course to exceed £3.6 billion in 2026, with annual growth running between 8% and 9%. For medispa clinic owners considering a sale, that growth translates directly into stronger buyer interest and rising valuation multiples. Whether you run a single-site Botox and dermal filler clinic in a regional town or a multi-location aesthetic platform across major cities, the M&A market for medispas has never been more active.
Private equity firms, healthcare consolidators and strategic acquirers are all competing for quality medispa assets. Skingevity launched in February 2026 with the acquisition of three leading UK clinics, backed by former Goldman Sachs and Boston Consulting Group principals. Bupa acquired The Dermatology Partnership from August Equity in late 2024, adding seven specialist clinics to its direct-to-consumer healthcare portfolio. Y1 Capital's Electiva Healthcare has been on an aggressive acquisition spree across Scottish and English aesthetics practices. These are not isolated events - they represent a structural shift in how institutional capital views the UK medical aesthetics sector.
This guide breaks down what your medispa clinic is worth in the current market, what drives multiples higher or lower, and how to position your business for a premium exit.
What Are Medispa EBITDA Multiples in 2026?
Medispa valuations in the UK sit within a well-defined range, driven primarily by revenue scale, treatment mix, recurring revenue models and clinical governance. The table below sets out current EBITDA multiple benchmarks based on transaction data from Scope Research and FOCUS Investment Banking's 2026 dashboard.
| Revenue Tier | Typical EBITDA Multiple | Key Drivers |
|---|---|---|
| Under £500K revenue | 2x - 4x EBITDA | Owner-dependent, single practitioner, limited treatment range |
| £500K - £2M revenue | 3x - 6x EBITDA | Small team, growing patient base, some treatment diversification |
| £2M - £5M revenue | 5x - 8x EBITDA | Multi-practitioner, membership models, established brand |
| £5M - £15M revenue | 7x - 10x EBITDA | Multi-site, strong management layer, diversified revenue |
| £15M+ revenue (platform) | 10x - 15x EBITDA | Regional or national brand, proven acquisition playbook, institutional-grade reporting |
Standalone medispa clinics typically transact at 4x to 7x EBITDA. Operators that demonstrate true platform characteristics - multi-location scale, recurring membership revenue, strong brand equity and device-based operating leverage - can command 10x to 12x EBITDA. Medspas tied to physician-led practices or surgical centres often earn a 1x to 3x EBITDA premium over standalone sites, reflecting the clinical supervision advantages and higher-acuity procedure capabilities.
For context, the broader UK medical practice market sees EBITDA multiples of 6x to 12x depending on specialty and scale. Dermatology platforms with aesthetic ancillaries currently trade at 12x to 15x EBITDA at the top end, making aesthetics one of the most sought-after sub-sectors in healthcare M&A.
Why Medispa Valuations Are Rising
Several structural factors are pushing medispa multiples upward in 2026.
Cash-Pay Revenue Model
Unlike most healthcare businesses that depend on NHS contracts or insurance reimbursement, medispas operate almost entirely on a cash-pay basis. Buyers love this. There is no reimbursement risk, no coding complexity and no payer concentration. Revenue is driven by consumer demand, which according to PolicyBee's 2026 industry analysis continues to grow at 8% to 9% annually in the UK alone.
Recurring Treatment Demand
Botox requires repeat treatments every three to four months. Dermal fillers last six to eighteen months. Skin rejuvenation programmes run over multiple sessions. This built-in repeat cycle gives medispas a naturally recurring revenue base that acquirers value highly. Clinics that have formalised this through membership or subscription plans command premium multiples.
Incoming Regulation Creates a Moat
The UK Government is introducing a mandatory licensing scheme for aesthetic practitioners in 2026. The House of Commons Women and Equalities Commission has pressed for accelerated regulatory action, with licensing requirements expected to cover both practitioners and premises. Research from UCL identified 19,701 practitioners across 5,589 clinics in the UK, many operating without adequate clinical oversight.
For well-run, compliant medispas, this regulation is a significant competitive advantage. Clinics already registered with Save Face (the government-approved register for medical aesthetics), accredited by the JCCP (Joint Council for Cosmetic Practitioners), or operating under CQC registration where required will find themselves in a strengthened market position. Less compliant operators will either need to invest heavily in meeting new standards or exit the market entirely - both scenarios that benefit established clinics.
Explosive Market Growth
The UK aesthetic medicine market generated USD 1.85 billion in revenue in 2024 and is projected to reach USD 7.53 billion by 2033, representing a compound annual growth rate of 17% according to Grand View Research. Injectable treatments such as Botox and dermal fillers now account for 65% of the UK aesthetics market's total revenue. The global aesthetic injectables market grew from USD 13.97 billion in 2025 to USD 15.45 billion in 2026, and the trajectory shows no signs of slowing.
Preparing Your Medispa for Sale
Achieving a premium multiple requires preparation that typically begins 18 to 24 months before going to market. Here are the areas that matter most to buyers.
Reduce Owner Dependence
The single biggest value killer in medispa transactions is owner dependence. If you are the lead practitioner performing 60% or more of treatments, buyers will discount your valuation significantly. Build a team of qualified practitioners who can maintain patient relationships and treatment outcomes without your daily involvement.
Hire a clinic manager who handles day-to-day operations. Document all clinical protocols, treatment plans and standard operating procedures. Ensure your Patient Management System captures comprehensive treatment records that are not tied to a single practitioner's personal notes.
Clean Your Financial Reporting
Buyers and their advisers will scrutinise your financials in detail. Separate personal expenses from business costs. Ensure your accounts clearly distinguish between treatment revenue streams - injectables, laser treatments, skin rejuvenation, body contouring and retail product sales. Present at least three years of clean management accounts showing EBITDA progression.
Calculate your adjusted EBITDA by adding back owner salary, one-off costs, personal vehicle expenses and any other items that would not continue under new ownership. This normalised figure is what buyers will multiply to arrive at your enterprise value. Our complete guide to EBITDA optimisation covers seven strategies that consistently increase business value.
Formalise Recurring Revenue
Clinics with membership or subscription models command the highest multiples. If you do not already offer a membership programme, introduce one that bundles regular treatments (such as quarterly Botox with annual skin assessments) at a slight discount. This gives buyers confidence in revenue predictability and patient retention.
Track and report your patient retention rate, average revenue per patient, treatment frequency and membership renewal rates. These operational KPIs are as important as financial statements during due diligence.
Invest in Clinical Governance
With the new regulatory framework approaching, buyers are placing increased weight on clinical governance structures. Ensure you have documented prescribing protocols, adverse event reporting procedures, up-to-date practitioner training records and proper medical indemnity insurance for all staff. If your clinic performs CQC-regulated activities, your registration must be current and inspection ratings strong.
The Buyer Landscape for UK Medispas
The medispa acquisition market in the UK is being driven by several distinct buyer types, each with different motivations and valuation approaches.
PE-Backed Platform Builders
Private equity firms are the most active buyers in UK aesthetics M&A. They acquire a "platform" clinic or group and then bolt on smaller practices to build scale. Y1 Capital's Electiva Healthcare exemplifies this strategy - acquiring La Belle Forme in Scotland and partnering with MYA Cosmetic Surgery to expand its UK-wide network. Skingevity, backed by former Goldman Sachs and BCG professionals, is pursuing the same playbook with its initial three-clinic acquisition. These buyers typically pay 5x to 8x EBITDA for add-on acquisitions and 8x to 12x for platforms. If you are interested in understanding how PE-backed buyers evaluate acquisition targets, the key metrics are EBITDA margin, revenue per practitioner, patient retention and geographic positioning.
Strategic Healthcare Groups
Large healthcare operators like Bupa are entering aesthetics through strategic acquisitions. Bupa's acquisition of The Dermatology Partnership from August Equity in late 2024 signals that major corporates see dermatology and aesthetics as a core growth channel in direct-to-consumer healthcare. These buyers often pay premium multiples because they can extract synergies through their existing patient networks, marketing infrastructure and clinical governance frameworks.
International Consolidators
Cross-border interest in UK aesthetics is growing. The February 2026 launch of Skingevity, founded by Italian professionals with experience at Goldman Sachs and BCG, illustrates how international capital is targeting UK clinics. As the UK market matures and regulation tightens, it becomes more attractive to sophisticated overseas buyers who value regulatory clarity and market structure.
Individual Practitioner Buyers
Qualified aesthetic practitioners looking to step into ownership represent a significant buyer pool for smaller clinics. These transactions tend to be at the lower end of the multiple range (3x to 5x EBITDA) and often involve seller financing or earn-out structures. They can, however, complete quickly with less complex due diligence.
The Sale Process for a Medispa Clinic
A typical medispa sale process runs between six and twelve months from initial preparation to completion. Here is what to expect.
Phase 1: Valuation and Preparation (Months 1-3)
Your adviser will conduct a thorough valuation, analysing your financial performance, patient data, treatment mix, staff contracts and property arrangements. This phase includes normalising your financials, identifying value drivers and addressing any red flags before going to market.
Phase 2: Marketing and Buyer Identification (Months 3-5)
A confidential information memorandum is prepared and shared with pre-qualified buyers. Your adviser maintains confidentiality throughout - staff, patients and competitors should not learn of the sale at this stage. The right adviser will have existing relationships with PE firms, healthcare consolidators and strategic buyers active in UK aesthetics.
Phase 3: Offers and Negotiation (Months 5-7)
Shortlisted buyers submit indicative offers. These will typically include an enterprise value (expressed as an EBITDA multiple), proposed deal structure (cash, equity rollover, earn-out), and post-completion expectations regarding your continued involvement.
Phase 4: Due Diligence and Completion (Months 7-12)
The selected buyer conducts detailed financial, legal, clinical and operational due diligence. For medispas, this will include a deep review of practitioner qualifications, treatment protocols, patient consent processes, clinical governance documentation and regulatory compliance. TUPE regulations will apply to your staff, and any property leases will need to be assignable or renegotiated. Our guide on red flags that kill M&A deals outlines the issues that most commonly derail healthcare transactions.
Tax Considerations
If you are planning to sell before April 2026, the current Business Asset Disposal Relief rate of 14% applies to qualifying gains up to the £1 million lifetime limit. From 6 April 2026, this rate increases to 18%. For a clinic selling at £2 million, this change could represent an additional £40,000 in CGT on the first £1 million of qualifying gains. Early preparation and tax planning with your accountant is essential.
What Makes a Medispa Worth More?
Beyond the fundamentals of revenue and EBITDA, specific characteristics drive medispa valuations to the upper end of the multiple range.
Treatment diversification. Clinics offering a broad range of services - injectables, laser treatments, skin rejuvenation, body contouring, medical-grade skincare and wellness services - command higher multiples than those relying heavily on a single treatment type. The trend toward medical wellness and longevity services is creating additional revenue streams, with 34% of aesthetics practices now offering these treatments.
Technology investment. Device-heavy medispas using advanced laser platforms, radiofrequency equipment and subscription-based treatment models attract stronger buyer interest. According to FOCUS Investment Banking, device-driven medispa models map to medtech multiples of 8.2x to 14.4x EBITDA.
Strong brand and patient loyalty. Clinics with recognisable brands, active social media presence, genuine patient testimonials and high Google review ratings are worth more. Patient lifetime value is a critical metric - buyers want to see that patients return repeatedly over multiple years.
Geographic positioning. Practices in affluent urban areas with high disposable income demographics command premium multiples. However, buyers also value clinics in underserved areas where competition is limited and growth potential is significant.
Data and systems. Modern patient management systems, CRM tools, online booking platforms and automated marketing funnels demonstrate operational maturity. Buyers want businesses that can scale - and scalability depends on systems, not individuals.
You can find more about how DealFlowAgent supports business owners through this process in our guides on selling a pest control business and selling a landscaping business, which cover similar valuation principles across different service sectors.
Frequently Asked Questions
How much is my medispa clinic worth?
Most standalone UK medispa clinics sell for between 4x and 7x EBITDA. A clinic generating £200,000 in annual EBITDA would typically be valued between £800,000 and £1.4 million. Clinics with multiple locations, membership models and strong clinical governance can command 8x to 12x EBITDA.
What EBITDA multiple do medspas sell for in the UK?
Small medspas with revenue under £2 million typically sell for 3x to 6x EBITDA. Mid-sized clinics with revenue between £2 million and £5 million achieve 5x to 8x EBITDA. Larger multi-site platforms with revenue above £5 million can reach 7x to 12x EBITDA, with exceptional platforms achieving even higher multiples.
Who is buying medispa clinics in the UK?
Private equity firms are the most active buyers, operating through platform and bolt-on acquisition strategies. Strategic healthcare groups like Bupa are entering the space. New consolidation platforms like Skingevity and Electiva Healthcare are acquiring multiple clinics to build national networks. Individual practitioners also acquire smaller single-site clinics.
How long does it take to sell a medispa?
A typical sale process takes six to twelve months from preparation to completion. Complex transactions involving multiple sites, regulatory considerations or international buyers may take longer. Starting preparation 18 to 24 months before your target sale date gives you time to optimise your business and maximise value.
Will the new UK aesthetics regulation affect my valuation?
Yes, positively - if you are already compliant. The incoming mandatory licensing scheme for aesthetic practitioners and premises will raise barriers to entry and force non-compliant operators to invest or exit. Clinics with Save Face accreditation, JCCP registration, strong clinical governance and CQC registration where applicable will be more valuable to buyers who need assurance of regulatory readiness.
What is the best time to sell a medispa?
Market conditions in 2026 are favourable, with strong buyer demand and rising multiples. The BADR tax rate increases from 14% to 18% from April 2026, making earlier completion advantageous for tax purposes. Seasonally, aesthetics revenue tends to peak in autumn and winter - selling after a strong Q4 demonstrates earning power.
Do I need to stay on after selling my medispa?
Most PE buyers expect the selling owner to remain for a transition period of 12 to 24 months, particularly if the owner is a key practitioner. Some buyers require an equity rollover of 20% to 30%, allowing the seller to benefit from future growth. Strategic buyers like Bupa may be more flexible on transition terms if the management team is strong.
How do I prepare my medispa for sale?
Focus on reducing owner dependence, building a strong practitioner team, formalising membership or subscription revenue, cleaning financial reporting, investing in clinical governance documentation and ensuring regulatory compliance. Begin this preparation 18 to 24 months before going to market.
What due diligence will a buyer conduct?
Buyers will review financial accounts, tax returns, patient data (anonymised), treatment protocols, practitioner qualifications, insurance policies, property leases, staff contracts (with TUPE implications), regulatory registrations, equipment maintenance records and clinical governance documentation. Aesthetic-specific due diligence will focus heavily on clinical safety records and practitioner compliance.
Should I use an M&A adviser to sell my medispa?
An experienced healthcare M&A adviser adds significant value through buyer identification, competitive tension in the process, deal structuring and negotiation expertise. Advisers with specific aesthetics sector knowledge understand the buyer landscape and can identify PE firms and consolidators actively seeking medispa acquisitions. The commission typically ranges from 3% to 6% of the transaction value, often recovering many times that in a higher sale price.
Take the Next Step
The UK medispa market is in a period of unprecedented buyer demand, rising valuations and structural consolidation. As we covered in our analysis of healthcare business exits, medical practices are consistently achieving higher valuations than many owners expect. If you are considering a sale in 2026 or 2027, the preparation you do now will directly impact the multiple you achieve.
DealFlowAgent specialises in connecting medispa and aesthetic clinic owners with PE-backed platforms, strategic healthcare buyers and international consolidators. Our AI-powered deal matching identifies the buyers most likely to pay a premium for your specific clinic profile.
Book a confidential valuation call to understand what your medispa is worth in today's market and how to position for a premium exit.
Experienced Dealmakers Lead Your Exit
Every exit is led by a senior advisor who has been through it themselves. Meet the team who will guide you.
Emerson Patton
Sector Specialist: Building, Construction & Trade Services
- •20+ years advising owners in building services, fire safety, HVAC, plumbing, and construction
- •Guided 200+ companies through growth, profit improvement, and exit planning
- •Builds equity value and operational structure long before a sale
- •Partners with DFA to prepare owners for exit while the advisory team runs the sale
Sage
AI Deal Concierge
- •Available 24/7. Monitors every signal in your deal
- •Keeps your advisory team one step ahead at all times
- •Trained on thousands of M&A transactions
- •Founded Fanbytes, scaled revenues to £10m+, exited at multi-eight-figure valuation
- •Advises on multiple M&A deals, invests in early-stage ventures
- •Built 700,000+ follower community teaching founders to scale and sell
- •Partnered with DealFlowAgent to expand access for founders to buyers
Sector Expert
Industry-Specific M&A Advisor
For every deal, our advisory team includes a sector specialist from that client's specific industry and niche: bringing relationships, insider knowledge, and leverage to support your process and achieve the best acquisition outcome.
Medispas & Aesthetic Clinics M&A Specialists
Thinking of selling your medispas & aesthetic clinics business?
DealFlowAgent is the UK and US's only M&A advisory firm specialising in medispa and aesthetic clinic businesses. Our trusted advisors leverage industry knowledge, buyer relationships and proprietary technology to help business owners secure multiple acquisition offers at higher valuations.
Talk to a Real Advisor - No Obligation
Speak with Joe or Sam about your situation. No hard sell, no commitment, just honest advice from advisors who've been through it.
What's Your Business Actually Worth?
Our valuation tool gives you a realistic range based on recent comparable transactions in your sector. Takes 3 minutes.
Joe Lewin
Exited entrepreneur and M&A advisor who has guided 20+ business owners through successful exits. Joe built and sold his first company after scaling to 80,000+ users and raised over £2M in funding. He founded DealflowAgent to combine traditional M&A expertise with AI technology, creating aligned advisory solutions for SME business owners. Joe regularly speaks on exit planning and M&A trends, and has built a network of thousands of strategic acquirers across UK and US markets.
